Merck & Co., Inc. (NYSE:MRK) Trading Down 0.9% - What's Next?

Merck & Co., Inc. (NYSE:MRK - Get Free Report) dropped 0.9% during mid-day trading on Wednesday . The stock traded as low as $92.86 and last traded at $93.91. Approximately 2,349,578 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 10,066,487 shares. The stock had previously closed at $94.73.

Analyst Ratings Changes

MRK has been the topic of a number of recent research reports. UBS Group cut their price target on shares of Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res raised Merck & Co., Inc. from a "hold" rating to a "strong-buy" rating in a report on Wednesday, December 4th. HSBC upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $130.00 price target on the stock in a research report on Wednesday, December 4th. BMO Capital Markets lowered their price objective on Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a research report on Wednesday, February 5th. Finally, Bank of America reduced their target price on Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating on the stock in a report on Wednesday, February 5th. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $117.12.

Merck & Co., Inc. Stock Performance

The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company has a fifty day moving average price of $93.87 and a 200 day moving average price of $102.25. The stock has a market cap of $235.92 billion, a P/E ratio of 13.85, a P/E/G ratio of 0.77 and a beta of 0.35.

Remove Ads

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing analysts' consensus estimates of $1.85 by ($0.13). Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business had revenue of $15.62 billion for the quarter, compared to the consensus estimate of $15.51 billion. During the same quarter last year, the firm posted $0.03 EPS. The business's revenue for the quarter was up 6.8% compared to the same quarter last year. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a $0.81 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.47%. Merck & Co., Inc.'s dividend payout ratio is presently 48.14%.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback plan on Tuesday, January 28th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to buy up to 4.1% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its stock is undervalued.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, Director Inge G. Thulin bought 2,833 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares in the company, valued at approximately $258,837.25. The trade was a 2,833.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Cristal N. Downing sold 2,361 shares of Merck & Co., Inc. stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $88.76, for a total value of $209,562.36. Following the sale, the insider now owns 7,085 shares in the company, valued at $628,864.60. This trade represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tradewinds LLC. grew its position in Merck & Co., Inc. by 0.6% during the third quarter. Tradewinds LLC. now owns 15,649 shares of the company's stock valued at $1,777,000 after buying an additional 101 shares during the period. CGN Advisors LLC boosted its stake in Merck & Co., Inc. by 0.4% in the fourth quarter. CGN Advisors LLC now owns 26,969 shares of the company's stock valued at $2,683,000 after acquiring an additional 102 shares during the last quarter. Accredited Investors Inc. grew its position in shares of Merck & Co., Inc. by 0.9% during the 3rd quarter. Accredited Investors Inc. now owns 11,834 shares of the company's stock valued at $1,344,000 after acquiring an additional 109 shares during the period. Cypress Wealth Services LLC increased its stake in shares of Merck & Co., Inc. by 3.1% during the 4th quarter. Cypress Wealth Services LLC now owns 3,639 shares of the company's stock worth $362,000 after purchasing an additional 111 shares during the last quarter. Finally, TI Trust Inc. increased its stake in shares of Merck & Co., Inc. by 0.6% during the 4th quarter. TI Trust Inc. now owns 19,834 shares of the company's stock worth $1,973,000 after purchasing an additional 111 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.